A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. - Wikidata - wikimedia - TriplyDB

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

http://www.wikidata.org/entity/Q34376103

about

The amyloid hypothesis of Alzheimer's disease at 25 years Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer's disease and Parkinson's disease No quiet surrender: molecular guardians in multiple sclerosis brain Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team Associating a negatively charged GdDOTA-derivative to the Pittsburgh compound B for targeting Aβ amyloid aggregates.Neuroimaging in pre-motor Parkinson's disease A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies.Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia.Monomeric ß-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons.The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations Mathematical model on Alzheimer's disease The need for thorough phase II studies in medicines development for Alzheimer's disease.The FDA-approved natural product dihydroergocristine reduces the production of the Alzheimer's disease amyloid-β peptides Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots.Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function.A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.Protein misfolding in neurodegenerative diseases: implications and strategies.Biometals and their therapeutic implications in Alzheimer's disease.Supersaturation is a major driving force for protein aggregation in neurodegenerative diseases.Rab21, a Novel PS1 Interactor, Regulates γ-Secretase Activity via PS1 Subcellular Distribution.Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis.Polygenic risk score analysis of pathologically confirmed Alzheimer disease.Alzheimer Disease: Scientific Breakthroughs and Translational Challenges.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.Coordinate-Based Meta-Analysis of the Default Mode and Salience Network for Target Identification in Non-Invasive Brain Stimulation of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Networks.Loss of stability and hydrophobicity of presenilin 1 mutations causing Alzheimer's disease.Twenty Years of Presenilins--Important Proteins in Health and Disease.Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - A therapeutic opportunity?Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes.Calcium signaling and molecular mechanisms underlying neurodegenerative diseases.The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease.Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.Modeling the Aggregation Propensity and Toxicity of Amyloid-β Variants.

P2860

Q26749528-3995CFF2-8C13-459E-AA6F-7F5E9FAE0D7A Q26784569-8147AC95-01B5-4E18-A805-3C730C049A65 Q27311651-A003830B-D51C-48DD-8D79-C7E88E7A4C1C Q28084633-BD33B741-5116-49BF-89DF-387AF9190345 Q28468287-A8006406-74EC-4ABE-B1BB-5A68B5961A82 Q28595520-3C12B0E1-32CF-487F-BAA6-6BC1FF44AD8A Q31028845-CEF6A8B3-88BF-4088-AF7D-473325AC5DD5 Q33676222-EA25050E-9F19-4CE0-B7C1-718BF3B3A7B1 Q34518856-D4DD1B5E-7500-429F-B01C-250537F3F183 Q35695716-C51DC36E-AF08-48D8-8281-1F2CD0B5CD4F Q35813037-5E20C968-8CB9-410A-AE23-B4E5895ED4BB Q35925948-E03852A4-3E73-4ED8-9B14-E920A520A6EC Q36165011-2DF89D77-9EA4-43E8-BA7E-C934462AD2F3 Q36198218-25FC0A8D-6EEE-4CEB-BC4A-6E4E8931591E Q36206793-9CCE98F3-0A31-48B8-9648-F206069B12DA Q36280432-D2A968D1-7030-4985-B63E-9C4BB944DB9D Q36913723-E37ADF43-A711-4677-941A-BEB908D6CEF7 Q37323658-F7CFF776-7B56-43A2-A15F-E7854D23F9E0 Q37604055-DBAAEAB6-4804-4FB5-98A6-1D819CF7E92D Q37697832-4AF922F4-0734-4058-9A09-51A740A3D8DC Q38263669-5BE2DE87-5CEB-4C4A-8EFE-88571CE3DFD3 Q38338129-E42B14B7-F0AD-4BE3-9B61-35FCB023D101 Q38433126-0947C632-ECD5-4E45-ABB9-05DF5327E1E5 Q38628808-BDACCEFE-B084-4151-AE4C-536634E79830 Q38663636-E451D623-02FB-4C45-A19C-F6ED53EACAFE Q38670400-A9F5E5F1-402C-4BC0-8D7F-DFCA4F3710FF Q38675107-C96B51F4-CDA2-4BA1-BBB1-089C29E578AB Q38742951-5529E9E9-A7BE-40F2-890F-96831D8BB6E8 Q38807908-067A23AC-B8B1-40FE-B65E-94EE05357C4F Q38901566-7767E7F6-88A8-4385-BD4A-EC723FEC9E80 Q38921927-CE256CF9-BE7B-4FD5-949E-120959CB2F07 Q38938820-59424D55-EAC0-4F48-8DCA-52EDF6A1F4E1 Q38958106-C1EBEBAF-DCA1-4FDB-B2A4-5652A7828544 Q38983318-042B230D-AB03-44BD-A5CD-2B1F04A181BE Q39135845-7133C663-A91C-442F-BF7F-FCC6BA450DFB Q39152527-80E1AC1B-7FEF-4C3B-B923-6BBE9032BE2C Q39222469-E03D00D3-FA7F-4A60-8B15-F896C9CFBE92 Q39275834-52D2F22A-9CC6-4F10-94EA-CD52E4A9CF36 Q40283684-942D52BB-970C-4020-B7DD-9B40AC473F1A Q40506178-22EF705D-1FAD-4E6D-B7CC-F55837B0D8B0

P2860

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

http://www.wikidata.org/entity/Q34376103

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A critique of the drug discove ...... othesis for Alzheimer disease.

@ast

A critique of the drug discove ...... othesis for Alzheimer disease.

@en

A critique of the drug discove ...... othesis for Alzheimer disease.

@nl

type

label

A critique of the drug discove ...... othesis for Alzheimer disease.

@ast

A critique of the drug discove ...... othesis for Alzheimer disease.

@en

A critique of the drug discove ...... othesis for Alzheimer disease.

@nl

prefLabel

A critique of the drug discove ...... othesis for Alzheimer disease.

@ast

A critique of the drug discove ...... othesis for Alzheimer disease.

@en

A critique of the drug discove ...... othesis for Alzheimer disease.

@nl

P1433

Q34376103-36946B1D-A2B4-4DB9-B3F2-809C380E6E41

P1476

Q34376103-815B9366-F848-4756-818D-4EEF54418EB7

P2093

Q34376103-36E83B6B-F279-414C-8368-908E386226F5

P275

Q34376103-FF984681-2165-446A-BF36-EF22A7F3D74C

P2860

Q34376103-0142CA56-3FC5-47AF-8367-C45B17357420

Q34376103-03494E67-7884-4E96-BC2E-EA8A1769B60A

Q34376103-0B1FFFF8-5EEB-41B3-BE2A-F33251900986

Q34376103-0B9B4B6D-CE1F-467C-A578-D588121E00FA

Q34376103-0C0BADAA-F4BD-4A51-A7B8-F2AFD5D92FD0

Q34376103-0C148660-71FC-4513-B884-9853459040B0

Q34376103-0DE50BF1-6FF9-4447-8715-B9BC8982F0B5

Q34376103-1772E0F8-8D0F-4948-B414-A843D1AB5DA3

Q34376103-1F8F75CF-7D56-4FB2-B66B-F68207245F63

Q34376103-22098EB3-114C-454C-9F39-11F0CDB05243

P304

Q34376103-168BA715-D768-4095-BD67-21B95AB98FF7

P31

Q34376103-898C094F-B17A-48FA-9D80-9BD292F30D6F

Q34376103-BFE0855D-60AC-4395-84C6-CA0DB2A737B1

P356

Q34376103-2CA41F8D-E942-42A9-A184-39269D294BC2

P433

Q34376103-DC08D8BB-A397-495D-884E-7937245106F3

P478

Q34376103-8D674C90-FBCF-424A-A36C-CE98282390DB

P50

Q34376103-7AC03500-065D-4B5D-A04E-6AB3B4F98C77

P5008

Q34376103-A9E87AA4-A4AC-47E0-8C5A-2B3A47972F8F

P577

Q34376103-2BA29C80-E1CD-4EBF-9105-BE0F74ED6104

Q34376103-51E09918-70E8-4CF4-A698-FFE24A6C8CD2

P698

Q34376103-1B7DAAD4-D6A8-434D-A949-32E815F781FD

P921

Q34376103-3E763BC2-0DE1-4870-8E1C-C90B67709BEE

Q34376103-8658E766-360B-4F26-9DD8-5C8FF7054755

P932

Q34376103-DF4B2CAE-555D-4D5C-8132-4151D8D03400

P356

P1433

Annals of Neurology

P1476

A critique of the drug discove ...... othesis for Alzheimer disease.

@en

P2093

Eric Karran

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease

Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

Neuropathological stageing of Alzheimer-related changes

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

P304

185-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.24188

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

John Anthony Hardy

P5008

P577

2014-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24853080

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

biomedical investigative technique

P932

4204160

http://www.w3.org/2001/XMLSchema#string